Literature DB >> 2330551

Assessment of reversibility of airway obstruction in patients with chronic obstructive airways disease.

M Nisar1, M Walshaw, J E Earis, M G Pearson, P M Calverley.   

Abstract

Spirometry before and after an inhaled beta agonist or a course of oral prednisolone is widely used to detect reversible airflow limitation in patients with chronic obstructive lung disease. How many of these patients have a response and how the response to beta agonists relates to the response to corticosteroids is not clear. In 127 outpatients (mean (SD) FEV1 0.92 (0.38) 1) who had a clinical diagnosis of chronic obstructive lung disease (continuous breathlessness for more than six months and an FEV1/forced vital capacity (FVC) ratio less than 60%) and who appeared to be stable, the change in FEV1 was measured after salbutamol 200 micrograms from a metered dose inhaler and 5 mg from a nebuliser. Symptoms and spirometric values were recorded before and after two weeks of oral prednisolone 30 mg. Reversibility was defined as a response in FEV1 of 15% or more from baseline alone and as a 15% change and a minimum increase of at least 200 ml. The latter gave results that showed greater internal consistency between the drug regimens. On the basis of this criterion 56 patients (44%) had no response to salbutamol or prednisolone, 71 responded to salbutamol (including all 27 steroid responders), and 25 patients had a response to salbutamol 5 mg but not to 200 micrograms. In general, the largest increase in FEV1 after salbutamol occurred in the subjects with greatest improvement after prednisolone. Subjects showing a response in FEV1 after two weeks' prednisolone had a fall in total symptom score, unlike those who had no response to any treatment or a response to salbutamol only. These data show that reversibility in response to beta agonists is common in patients diagnosed on clinical grounds as having stable chronic obstructive lung disease, that it can be substantial, and that it is best detected by using a larger dose of salbutamol. Salbutamol responders were those most likely to improve after a trial of oral prednisolone. Allowance should be made for the variability of FEV1 in the calculation of the percentage response at low baseline values (less than 1 litre).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2330551      PMCID: PMC462381          DOI: 10.1136/thx.45.3.190

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  8 in total

1.  Use of pressurised aerosols by asthmatic patients.

Authors:  I C Paterson; G K Crompton
Journal:  Br Med J       Date:  1976-01-10

2.  Short term variability in FEV1 and bronchodilator responsiveness in patients with obstructive ventilatory defects.

Authors:  P M Tweeddale; F Alexander; G J McHardy
Journal:  Thorax       Date:  1987-07       Impact factor: 9.139

3.  Evaluation of the turbine pocket spirometer.

Authors:  K A Gunawardena; K Houston; A P Smith
Journal:  Thorax       Date:  1987-09       Impact factor: 9.139

4.  Effects of prednisolone in chronic airflow limitation.

Authors:  D M Mitchell; P Gildeh; M Rehahn; A H Dimond; J V Collins
Journal:  Lancet       Date:  1984-07-28       Impact factor: 79.321

5.  Corticosteroids in COPD. A clinical trial and reassessment of the literature.

Authors:  O Eliasson; J Hoffman; D Trueb; D Frederick; J R McCormick
Journal:  Chest       Date:  1986-04       Impact factor: 9.410

6.  Bronchodilator response in chronic obstructive pulmonary disease.

Authors:  N R Anthonisen; E C Wright
Journal:  Am Rev Respir Dis       Date:  1986-05

7.  Steroid response in stable chronic obstructive pulmonary disease.

Authors:  L A Mendella; J Manfreda; C P Warren; N R Anthonisen
Journal:  Ann Intern Med       Date:  1982-01       Impact factor: 25.391

8.  The use of the 12 minute walking test in assessing the effect of oral steroid therapy in patients with chronic airways obstruction.

Authors:  J F O'Reilly; J M Shaylor; K M Fromings; B D Harrison
Journal:  Br J Dis Chest       Date:  1982-10
  8 in total
  13 in total

1.  BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS.

Authors: 
Journal:  Thorax       Date:  1997-12       Impact factor: 9.139

Review 2.  Lung volume reduction surgery in chronic obstructive pulmonary disease.

Authors:  L Davies; P M Calverley
Journal:  Thorax       Date:  1996-08       Impact factor: 9.139

Review 3.  Economic burden of chronic obstructive pulmonary disease. Impact of new treatment options.

Authors:  M Friedman; D E Hilleman
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

4.  Relationship between bronchial reversibility and tracheobronchial clearance in patients with chronic bronchitis.

Authors:  M Moretti; M T Lopez-Vidriero; D Pavia; S W Clarke
Journal:  Thorax       Date:  1997-02       Impact factor: 9.139

5.  Capsaicin responsiveness and cough in asthma and chronic obstructive pulmonary disease.

Authors:  M J Doherty; R Mister; M G Pearson; P M Calverley
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

6.  Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease.

Authors:  P M A Calverley; A Lee; L Towse; J van Noord; T J Witek; S Kelsen
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

7.  Underdiagnosed asthma in South Australia.

Authors:  R J Adams; D H Wilson; S Appleton; A Taylor; E Dal Grande; C R Chittleborough; R E Ruffin
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

8.  Variability of bronchodilator response and effects of inhaled corticosteroid treatment in obstructive airways disease. Dutch CNSLD Study Group.

Authors:  H A Kerstjens; P L Brand; P H Quanjer; B A van der Bruggen-Bogaarts; G H Koëter; D S Postma
Journal:  Thorax       Date:  1993-07       Impact factor: 9.139

9.  Diagnosing COPD.

Authors:  David M G Halpin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

10.  Predictive value and utility of oral steroid testing for treatment of COPD in primary care: the COOPT study.

Authors:  Niels H Chavannes; Tjard R J Schermer; Emiel F M Wouters; Reinier P Akkermans; Richard P N Dekhuijzen; Jean W M Muris; Chris van Weel; Onno C P van Schayck
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.